Geron's latest hire was the key behind the Pfizer-Medivation $14B merger......

Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Post Reply
kmall
Posts: 753
Joined: Thu Mar 21, 2019 3:57 pm

Geron's latest hire was the key behind the Pfizer-Medivation $14B merger......

Post by kmall » Wed Mar 30, 2022 12:05 pm

Aron Feingold - Vice President, Investor Relations & Corporate Communication, Geron Corporation

Hired - March 2022

3/17/2022 - FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN) reported that it has granted non-statutory stock options to purchase an aggregate of 320,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. Aron Feingold is one of these employees.
https://ir.geron.com/investors/press-re ... fault.aspx

Former Employers: Pfizer, Medivation, Sangamo Therapeutics, Ruder Finn

Aron Feingold accomplishments: Medivation June 2016 - Dec 2016
"Led internal integration and change management comms for acquisition, one of the largest in biopharma"


Pfizer/Medivation acquisition - Aug 22, 2016
https://www.genengnews.com/news/pfizer- ... n-for-14b/


Pfizer to Acquire Medivation for $14B

Pfizer is acquiring Medivation for $14 billion, the companies said today, in a deal that expands the pharma giant’s cancer portfolio—and far exceeds two unsuccessful offers for the San Francisco biotech made over the past 4 months by Sanofi.

“The addition of Medivation will strengthen Pfizer’s Innovative Health business and accelerate its pathway to a leadership position in oncology, one of our key focus areas, which we believe will drive greater growth and scale of that business over the long-term,” Pfizer Chairman and CEO Ian Read said in a statement.

At $81.50 a share, Pfizer’s offer marks a 21% premium over Medivation’s Friday closing share price of $67.19, and a 55% premium over Sanofi’s first offer for Medivation of $52.50 a share, or $9.3 billion.

Medivation rejected Sanofi’s first offer in June, and a month later turned down a sweetened $10 billion offer consisting of $58 per share in cash and a $3 per share contingent value right tied to sales of talazoparib.



**About 2 months ago both Pfizer CEO - Albert Bourla and Novartis CEO - Vas Narasimhan were listed on Geron CEO - Dr John Scarlett's Linkedin page as "Influencers"

Some strong connections here with the Aron Feingold hiring.......Pfizer/Sanofi/Novartis

The next week or so should be interesting. -Kmall

Ryan
Posts: 348
Joined: Sat Jul 08, 2017 1:41 pm

Re: Geron's latest hire was the key behind the Pfizer-Medivation $14B merger......

Post by Ryan » Thu Mar 31, 2022 4:31 am

My favorite part is the “one of the largest in the history of biopharma” part.

Post Reply